WO2014165113A1 - Fils d'acide hyaluronique réticulé pour le traitement de stries - Google Patents

Fils d'acide hyaluronique réticulé pour le traitement de stries Download PDF

Info

Publication number
WO2014165113A1
WO2014165113A1 PCT/US2014/024441 US2014024441W WO2014165113A1 WO 2014165113 A1 WO2014165113 A1 WO 2014165113A1 US 2014024441 W US2014024441 W US 2014024441W WO 2014165113 A1 WO2014165113 A1 WO 2014165113A1
Authority
WO
WIPO (PCT)
Prior art keywords
hyaluronic acid
thread
cross
threads
linked
Prior art date
Application number
PCT/US2014/024441
Other languages
English (en)
Inventor
Arthur SWIFT
Nowell SOLISH
Geoffrey C. Gurtner
Kenneth N. Horne
Original Assignee
Allergan Holdings France S.A.S.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Holdings France S.A.S. filed Critical Allergan Holdings France S.A.S.
Publication of WO2014165113A1 publication Critical patent/WO2014165113A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0241—Containing particulates characterized by their shape and/or structure
    • A61K8/027—Fibers; Fibrils
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/10—Hair or skin implants
    • A61F2/105—Skin implants, e.g. artificial skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/28—Polysaccharides or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/20—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04—Macromolecular materials
    • A61L31/042—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/0059—Cosmetic or alloplastic implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/87—Application Devices; Containers; Packaging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/34—Materials or treatment for tissue regeneration for soft tissue reconstruction

Definitions

  • This disclosure relates generally to using threads of hyaluronic acid in treating striae.
  • Hyaluronic acid is a linear polysaccharide (i.e., non-sulfated glycosaminoglycan) consisting of a repeated disaccharide unit of alternately bonded ⁇ -D-N-acetylglucosamine and ⁇ -D- glucuronic acid which can be depicted by the formula:
  • Hyaluronic acid is sometimes referred to by the
  • biocompatible because of its lack of species and organ specificity and is often used as a biomaterial in tissue engineering and as a common ingredient in soft tissue augmentation products.
  • Natural hyaluronic acid has poor in vivo stability due to rapid enzymatic degradation and hydrolysis and, accordingly, various chemically modified forms of hyaluronic acid (e.g., cross-linked forms, ionically modified forms, esterified forms, etc.) have been synthesized to address this problem.
  • hyaluronic acid or cross-linked versions thereof are used in various gel forms, for example as soft tissue augmentation products, adhesion barriers, and the like.
  • Threaded forms of hyaluronic acid and its cross-linked versions have been developed that can be dispensed uniformly to specific locations regardless of tissue resistance, and without the risk of migration at implantation. These threaded forms are beneficial because they have improved tensile strength and greater ease of delivery to a variety of tissue locations. Summary
  • Threads have been developed comprising cross-linked hyaluronic acid. This disclosure describes the use of such threads for treating striae (stretch marks).
  • a method of treating a stria in a patient in need thereof comprising; a) inserting a thread into skin or subcutaneous space of the patient adjacent to or under the stria; and b) applying the thread adjacent to or under the stria, thereby treating the stria.
  • the thread comprises substantially cross-linked hyaluronic acid.
  • the thread comprises (i) cross-linked hyaluronic acid wherein the cross linked hyaluronic acid has been cross linked with butanediol diglycidyl ether (BDDE), and (ii) non-cross linked hyaluronic acid.
  • the hyaluronic acid is substantially cross-linked with at least about 15 mole % of a butanediol diglycidyl ether (BDDE) derivative relative to the repeating disaccharide unit of the hyaluronic acid, and at least about 5% noncross-linked hyaluronic acid relative to the weight of total hyaluronic acid solids.
  • BDDE butanediol diglycidyl ether
  • the thread is inserted into the skin of a patient adjacent to or under the stria.
  • the thread is then applied under the stria, thereby treating the stria.
  • the thread upon exposure to body fluids or by manually hydrating, the thread expands upon hydration and such expansion is typically sufficient to fill-in and/or improve the appearance of the stria. It is advantageous to have a thread expand upon hydration because the invasiveness of the insertion profile is minimized, however, threads designed to not expand can also be used to treat the stria.
  • several threads can be placed generally parallel to each other and additional threads can be placed in a generally perpendicular direction with respect to the first set of parallel threads thereby forming a mesh structure whose aggregate effect is to contour a larger striae.
  • the threads described herein can be prepared using a composition comprising substantially cross-linked hyaluronic acid, wherein hyaluronic acid is cross-linked with at least about 15 mole % of a butanediol diglycidyl ether (BDDE) derivative relative to the repeating disaccharide unit of the hyaluronic acid.
  • BDDE butanediol diglycidyl ether
  • the concentration of cross-linking agent, i.e. BDDE used to prepare the substantially cross-linked hyaluronic acid, is used to tune and/or improve certain physical properties of the thread.
  • the composition comprises at least 5% hyaluronic acid before cross-linking, such as 8%, 10% or 12% hyaluronic acid.
  • threads as described herein comprise both cross-linked and noncross-linked hyaluronic acid. Surprisingly, the relative concentrations of these two components was discovered to impact certain physical properties of the threads, which ultimately led to an increased in vivo effectiveness as soft tissue augmentation products.
  • thread manufacturing process e.g., rinsing, deaeration, extrusion, and drying of precursor gels, as well as the terminal sterilization of the dry threads
  • threads comprising cross-linked hyaluronic acid have been prepared with significant cross-linking (e.g., at least about 15% BDDE derivative) relative to the repeating disaccharide unit of the hyaluronic acid. This increased cross-linking within the cross-linked hyaluronic acid composition is
  • the hyaluronic acid threads described herein possess an increased in vivo half- life when compared to the hyaluronic acid threads described previously in the art.
  • sterilized threads described in the art were fully resorbed within 30 days whereas the threads described herein were still present at 3 months or longer in some cases.
  • a dry thread comprising substantially cross-linked hyaluronic acid prepared by the steps of: a) forming a substantially cross-linked hyaluronic acid composition by contacting hyaluronic acid with BDDE; b) adding noncross-linked hyaluronic acid to the composition; c) extruding the substantially cross-linked composition to form a wet thread; and d) drying the wet thread to form a dry thread.
  • Fig. 1 shows a schematic of hyaluronic acid cross-linked with butanediol diglycidyl ether (BDDE).
  • BDDE butanediol diglycidyl ether
  • Fig. 3A illustrates a close-up view of a thread inserted into the inner-diameter of a needle; and
  • Fig. 3B illustrates a close-up view of the proximal end of a solid needle with the thread overlapping the needle.
  • FIGs. 4A and 4B show a schematic of the contemplated microanatomy of a thread implanted into a patient both in cross-section of the skin and three-dimensional cross-section.
  • Figs. 5A, 5B, 5C, 5D and 5E show (at 14x magnification) a histological cross section of a rabbit, one month (5 A), two months (5B), three months (5C), six months (5D) and nine months (5E) after being treated with threads prepared from 8/40@ 15/20 thread composition (phosphate buffer wash; 15% HA solids, 20% of HA is noncross-linked binder in water). Details of the histological studies illustrated in Figs. 5A, 5B, 5C, 5D and 5E can be found in Example 9.
  • Fig. 6 shows a gross dissection of a rabbit one month after being treated with threads prepared from 8/40@ 15/20 thread composition (phosphate buffer wash; 15% HA solids, 20% of HA is noncross-linked HA binder). Details of the dissection illustrated in Fig. 6 can be found in Example 10.
  • Fig 7 shows a gross dissection of a rabbit two months after being treated with threads prepared from 8/40@ 15/20 thread composition (phosphate buffer wash; 15% HA solids, 20% of HA is noncross-linked HA binder). Details of this dissection illustrated in Fig. 7 can be found in Example 10.
  • AA/BB@XX/YY wherein (AA) is the weight % of hyaluronic acid relative to the weight of the cross-linking solution; (BB) is the weight % of BDDE relative to the weight of the hyaluronic acid; (XX) is the weight % of cross-linked and noncross-linked hyaluronic acid "solids" relative to the weight of the composition (pre-extrusion); and (YY) is the weight % of noncross-linked hyaluronic acid relative to the weight of total cross-linked and noncross-linked hyaluronic acid "solids”.
  • Fig. 8 shows the results of a thread degradation study with hyaluronidase (1 mg/mL).
  • Vertical arrows correspond to the addition of fresh 1 mg/mL of hyaluronidase.
  • Fig. 9 shows average palpation scores for exemplary threads as described herein. Details of these palpation studies represented in Fig. 9 can be found in Example 8.
  • Fig. 10 shows the particle size distribution of particles up to 0.3 square mm in diameter of the gel with one sizing and multiple sizing steps.
  • compositions and methods are intended to mean that the compositions and methods include the recited elements, but not excluding others.
  • Consisting essentially of when used to define compositions and methods shall mean excluding other elements of any essential significance to the combination for the stated purpose. Thus, a composition consisting essentially of the elements as defined herein would not exclude other materials or steps that do not materially affect the basic and novel characteristic(s) claimed.
  • Consisting of shall mean excluding more than trace elements of other ingredients and substantial method steps. Embodiments defined by each of these transition terms are within the scope of this disclosure.
  • hyaluronic acid or "HA” refers to the polymer having the formula:
  • n is the number of repeating units. All sources of hyaluronic acid are useful, including bacterial and avian sources. Hyaluronic acids useful have a molecular weight of from about 0.5 MDa (mega Dalton) to about 3.0 MDa. In some embodiments, the molecular weight is from about 0.6 MDa to about 2.6 MDa and in yet another embodiment, the molecular weight is from about 1.4 MDa to about 1.7 MDa. In some embodiments, the molecular weight is about 0.7 MDa and in yet another embodiment, the molecular weight is about 1.7 MDa. In some embodiments, the molecular weight is about 2.7 MDa.
  • cross-linked is intended to refer to two or more polymer chains of hyaluronic acid which have been covalently bonded via a cross-linking agent. Such cross-linking is differentiated from intermolecular or intramolecular dehydration which results in lactone, anhydride, or ester formation within a single polymer chain or between two or more chains. Although, it is contemplated that intramolecular cross- linking may also occur in the threads as described herein.
  • cross-linked is also intended to refer to hyaluronic acid covalently linked to a BDDE derivative. In some embodiments, the term “cross-linked” also refers to covalently modified hyaluronic acid.
  • Cross-linking agents contain at least two reactive functional groups that create covalent bonds between two or more molecules.
  • the cross-linking agents can be homobifunctional (i.e. have two reactive ends that are identical) or heterobifunctional (i.e. have two different reactive ends).
  • the cross-linking agents to be used in the present disclosure should comprise complimentary functional groups to that of hyaluronic acid such that the cross-linking reaction can proceed.
  • the cross-linking does not form esterified hyaluronic acid.
  • Suitable cross-linking agents include, by way of example only, butanediol diglycidyl ether (BDDE), divinyl sulfone (DVS), or 1- ethyl-3-(3-dimethylaminopropyl) carbodimide hydrochloride (EDC), or a combination thereof.
  • the cross-linking agent is BDDE.
  • the cross-linking agent is not a photocurable cross-linking agent.
  • BDDE derivative refers to a form of BDDE wherein one or both epoxides of BDDE have reacted with hyaluronic acid.
  • BDDE has the following chemical structure:
  • the BDDE derivative of hyaluronic acid can be covalently bound to hyaluronic acid at both ends with both epoxides having been reacted.
  • Additional BDDE derivatives of hyaluronic acid are contemplated herein.
  • certain BDDE derivatives of hyaluronic acid can be covalently bound at both ends between two separate hyaluronic acid polymers (i.e., cross- linked), while other BDDE derivatives can be covalently bound at both ends within a single hyaluronic acid polymer.
  • BDDE derivatives that are covalently bound at one or both ends to a hydroxyl group from one or more additional BDDE derivatives that are themselves covalently bound to hyaluronic acid are also contemplated.
  • BDDE derivatives that that are covalently bound to hyaluronic acid at just one end.
  • one of the epoxide rings can be opened by covalent attachment to a single stretch of a hyaluronic acid polymer while the other epoxide ring can remain closed (i.e., unreacted).
  • concentration of such BDDE derivatives with an unreacted epoxide is sufficiently low so as not to affect the biocompatibility of threads prepared from such compositions.
  • BDDE derivative in which one of the epoxide rings has been opened by covalent attachment to a single stretch of hyaluronic acid polymer while the other epoxide ring has been opened by hydrolysis.
  • the cross-linked hyaluronic acid compositions comprise at least about 2 mole % BDDE (with respect to the disaccharide monomer) which is covalently bound at both ends between two separate hyaluronic acid polymers.
  • the term "binder” refers to a naturally occurring or synthetic substance which provides uniform consistency and/or cohesion in the composition comprising the cross-linked hyaluronic acid, which when extruded, forms a thread.
  • the binder is noncross- linked hyaluronic acid.
  • the binder is selected from a group consisting of sugars and polysaccharides such as sucrose, maltose, chondroitin sulfate, dermatan sulfate, heparin, chitosan, cellulose, gelatin, collagen, acacia, starch, PVP (polyvinyl pyrrolidone), HPC
  • HPMC hydroxypropyl methylcellulose
  • PEG poly(lactic-co- glycolic acid)
  • carboxy methyl cellulose ethylcellulose
  • gelatin polyethylene oxide
  • dextrin magnesium aluminum silicate
  • polymethacrylates and the like.
  • skin refers to the three layers: the epidermis, the dermis, and the hypodermis or the deeper subcutaneous tissue.
  • the terms “smoother,” “smooth,” and “smoothness” refer to the property of a thread that provides decreased drag when pulled through tissue. The more smooth the thread, the less drag when pulled through the skin.
  • thread refers to a long, thin, flexible form of a material.
  • the thread as described herein can have a variety of shapes in the cross-section which are discussed below.
  • the term "ultimate tensile strength” is intended to refer to the tensile strength of the thread which has been normalized with respect to cross-sectional area.
  • the term “tensile strength” is intended to refer to the maximum stress a thread can withstand without failing when subjected to tension. In one embodiment, it is contemplated that the ultimate tensile strength is sufficient to pull the thread through the skin and manipulate it once in the skin such that the integrity of the thread is not substantially compromised by, for example, breaking or segmenting.
  • threads as described herein preferably have an ultimate tensile strength of about 3 kpsi ("kilopounds per square inch") or greater, or 5 kpsi or greater, or 10 kpsi or greater, or 15 kpsi or greater or 20 kpsi or greater or 50 kpsi or greater or 75 kpsi or greater.
  • the threads have a tensile strength of about 0.4 lbf (pound force) or greater, or 0.6 lbf or greater, or 0.8 lbf or greater, or 1.0 lbf or greater, or 1.1 lbf or greater.
  • the threads have a tensile strength of about 0.7 lbf.
  • tensile strength may be measured by using a force gauge and measuring the peak force required to break the thread. Of approximately 9 thread lots tested, the average tensile strength was about 0.71 pounds force using a 20 gauge extrusion nozzle.
  • percent moisture is intended to refer to the total percent of water by weight. In one embodiment, the percent moisture of the thread is about 30% or less, or alternatively, about 15% or less, or alternatively, about 10% or less. This can typically be measured by Karl Fisher titration.
  • substantially cylindrical refers to a thread wherein the cross-section of the thread is round.
  • the term “substantially” as used to refer to shapes of the threads means that at least 50% of the thread has the approximate shape described.
  • the term substantially is also used to encompass threads which have a variety shapes along the length of the thread. For example, a thread could be substantially cylindrical but the ends of the thread may be tapered.
  • the substantially cylindrical threads can be provided when the contact angle of the gel composition and the substrate on which it is extruded have an equilibrium contact angle of greater than about 90 degrees.
  • substantially D-shaped refers to a thread wherein the cross-section is D-shaped or substantially semi-circular.
  • the substantially D-shaped threads have one flat side and one substantially round side.
  • the substantially D-shaped threads can be provided when the contact angle of the gel composition and the substrate on which it is extruded have an equilibrium contact angle of about 90 degrees.
  • substantially ribbon-shaped refers to a thread wherein the thickness of the thread is less than about 50% of the width of the thread.
  • the cross-section is substantially rectangular.
  • the ribbon-shaped threads can be provided when the contact angle of the gel composition and the substrate on which it is extruded have an equilibrium contact angle of less than about 90 degrees.
  • the ribbon-shaped threads can be formed by cutting a wet gel to achieve the desired cross-sectional shape.
  • Ribbon-shaped may also include shapes that are substantially ellipsoidal.
  • substantially ellipsoidal refers to a thread wherein the cross- section is substantially oblong or elliptical.
  • the term "therapeutic agent” can include one or more therapeutic agents.
  • the therapeutic agent is an anesthetic, including but not limited to, lidocaine, xylocaine, novocaine, benzocaine, prilocaine, ripivacaine, propofol, or combinations thereof.
  • the therapeutic agent includes, but is not limited to, epinephrine, ephedrine, aminophylline, theophylline or combinations thereof.
  • the therapeutic agent is botulism toxin.
  • the therapeutic agent is laminin-51 1.
  • the therapeutic agent is glucosamine, which can be used, for example, in the treatment of regenerative joint disease.
  • the therapeutic agent is an antioxidant, including but not limited to, vitamin E or all-trans retinoic acid such as retinol.
  • the therapeutic agent includes stem cells.
  • the therapeutic agent is insulin, a growth factor such as, for example, NGF (nerve growth factor),BDNF (brain-derived neurotrophic factor), PDGF (platelet-derived growth factor) or Purmorphamine Deferoxamine NGF (nerve growth factor), dexamethasone, ascorbic acid, 5-azacytidine, 4,6-disubstituted
  • a growth factor such as, for example, NGF (nerve growth factor),BDNF (brain-derived neurotrophic factor), PDGF (platelet-derived growth factor) or Purmorphamine Deferoxamine NGF (nerve growth factor)
  • dexamethasone ascorbic acid, 5-azacytidine, 4,6-disubstituted
  • pyrrolopyrimidine cardiogenols, cDNA, DNA, RNAi, BMP-4 (bone morphogenetic protein-4), BMP- 2 (bone morphogenetic protein-2), an antibiotic agent such as, for example, ⁇ lactams, quinolones including fluoroquinolones, aminoglycosides or macrolides, an anti-fibrotic agent, including but not limited to, hepatocyte growth factor or Pirfenidone, an anti-scarring agent, such as, for example, anti- TGF-b2 monoclonal antibody (rhAnti-TGF-b2 mAb), a peptide such as, for example, GHK copper binding peptide, a tissue regeneration agent, a steroid, fibronectin, a cytokine, an analgesic such as, for example, Tapentadol HC1, opiates, (e.g., morphine, codone, oxycodone, etc.) an antiseptic, alpha- beta
  • diagnostic agent refers to an agent which is used as part of a diagnostic test (e.g., a fluorescent dye to be used for viewing the thread in vivo).
  • the diagnostic agent is soluble TB (tuberculosis) protein.
  • lubricity-enhancing agent is intended to refer to a substance or solution which when contacted with the dry thread, acts to lubricate the dry thread.
  • a lubricity- enhancing agent can comprise, for example, water and/or an alcohol, an aqueous buffer, and may further comprise additional agents such as polyethylene glycol, hyaluronic acid, and/or collagen.
  • biodegradation impeding agent is intended to refer to a biocompatible substance that slows or prevents the in vivo degradation of the thread.
  • a biodegradation impeding agent can include hydrophobic agents (e.g., lipids) or sacrificial biodegradation agents (e.g., sugars).
  • failure load is intended to refer to the maximum force which, when applied to the thread, causes the thread to fail. By “failing,” it meant that the thread can break or segment or otherwise lose structural integrity. In some embodiments, the failure load is about 0.1 pounds or 0.22 kilograms or greater.
  • the term "firm” is intended to refer to a cohesive material that maintains its form in an unconstrained environment (ie as opposed to a flowable/amorphous material) and demonstrates some degree of structural integrity under compression.
  • a gelatin cube is an example of a firm gel.
  • aqueous gel composition or “gel composition” or “gel mixture” is intended to refer to an aqueous composition comprising water, hyaluronic acid, and a cross-linking agent and/or cross-linked hyaluronic acid.
  • the composition may further comprise a buffer such that that the pH of the solution changes very little with the addition of components of the composition.
  • the composition is referred to as an aqueous buffered gel composition.
  • the pH of the buffered gel composition is typically from about 7 to about 13. In certain embodiments the pH is about 7. In certain embodiments, the pH is higher at about 9 or about 10.
  • the pH can be adjusted by adding an appropriate amount of a suitable base, such as Na 2 C0 3 or NaOH.
  • a suitable base such as Na 2 C0 3 or NaOH.
  • the aqueous gel buffered composition comprises phosphate buffered saline.
  • the aqueous gel buffered composition comprises tris(hydroxymethyl)aminomethane (Tris), which has the formula (HOCH 2 ) 3 CNH 2 .
  • Tris tris(hydroxymethyl)aminomethane
  • additional solutes are added to adjust the osmolarity and ion concentrations, such as sodium chloride, calcium chloride, and/or potassium chloride.
  • buffer is intended to refer to a solution that stabilizes pH, wherein the solution comprises a mixture of a weak acid and its conjugate base or a weak base and its conjugate acid.
  • Buffer solutions include, but are not limited to, 2-amino-2-methyl- l,3-propanediol, 2-amino-2- methyl- 1 -propanol, L-(+)-tartaric acid, D-(-)-tartaric acid, ACES, ADA, acetic acid, ammonium acetate, ammonium bicarbonate, ammonium citrate, ammonium formate, ammonium oxalate, ammonium phosphate, ammonium sodium phosphate, ammonium sulfate, ammonium tartrate, BES, BICINE, BIS-TRIS, bicarbonate, boric acid, CAPS, CHES, calcium acetate, calcium carbonate, calcium citrate, citrate, citric acid, diethanolamine, EPP,
  • aqueous solvent is intended to refer to a non-toxic, non-immunogenic aqueous composition.
  • the aqueous solvent can be water and/or an alcohol, and may further comprise buffers, salts (e.g., CaCy and other such non-reactive solutes.
  • the term "contact angle” or “equilibrium contact angle” refers to a measure of a liquid's affinity for a solid and quantifies the degree of a liquid drop's spread when placed on the solid.
  • the liquid is the aqueous gel composition and the rigid or solid surface is the substrate on which the composition is extruded.
  • the contact angle is a measure of the angle that the edge of an ideal drop makes with a flat surface. The lower that the contact angle is, the greater attraction between the surface and the liquid. For example, water spreads almost completely on glass and has a very low contact angle of nearly 0 degrees. Mercury, in contrast, beads up and spreads very little; its contact angle is very large.
  • stria refers to scarring on the skin. Stria are caused by the tearing of the dermis. Stria is meant to encompass the various forms of stria found throughout the body. Non-limiting examples include striae atrophicae, vergetures, stria distensae, striae cutis distensae, lineae atrophicae, linea albicante, and striae gravidarum.
  • treating refers to improving the appearance of the stria. Improving the appearance can refer to smoothing the stria so that it is less visable and appears even with the surrounding skin.
  • Threads comprising cross-linked hyaluronic acid have been prepared according to methods described herein having increased ratios of cross-linking agent (e.g., BDDE derivatives) relative to the repeating disaccharide unit of the hyaluronic acid.
  • cross-linking agent e.g., BDDE derivatives
  • hyaluronic acid (HA) used herein has a molecular weight of from about 0.5 MDa (mega Dalton) to about 3.0 MDa. In some embodiments, the molecular weight is from about 0.6 MDa to about 2.6 MDa, and in yet another embodiment the molecular weight is from about 1.4 MDa to about 1.7 MDa. In some embodiments, the molecular weight is about 0.7 MDa, and in yet another embodiment the molecular weight is about 1.7 MDa. In some embodiments, the molecular weight is about 2.7 MDa.
  • the treads comprise compositions comprising cross-linked hyaluronic acid formed under aqueous conditions. In certain embodiments, such aqueous compositions form gels.
  • the hyaluronic acid is hydrated for between about one minute and about 60 minutes prior to cross-linking. In other embodiments, the hyaluronic acid is hydrated for between about one hour and about 12 hours prior to cross-linking. In certain embodiments, the hyaluronic acid is hydrated for about one hour and in yet another embodiment the hyaluronic acid is allowed to hydrate for about two hours prior to cross-linking. In certain embodiments, the hyaluronic acid is hydrated for about three hours and in yet another embodiment the hyaluronic acid is allowed to hydrate for four hours prior to cross-linking.
  • the aqueous solution Prior to addition of the HA, the aqueous solution is adjusted to the desired pH.
  • the aqueous solution has a pH > about 7.
  • the solution has a pH of about 9, or about 10, or about 11, or about 12 or about 13, or greater than 13.
  • the solution comprises water and can optionally comprise phosphate buffered saline (PBS) or tris(hydroxymethyl)aminomethane (Tris) buffer.
  • PBS phosphate buffered saline
  • Tris tris(hydroxymethyl)aminomethane
  • the buffer can be selected based on the desired pH of the composition.
  • PBS can be used for compositions at a pH of about 7
  • Tris can be used for compositions having a higher pH of about 9 or about 10.
  • the pH is from between about 9 and about 13.
  • the pH is at least about 13. In some embodiments, the pH is adjusted with the appropriate amount of a suitable base, such as Na 2 C0 3 or NaOH to reach the desired pH. In some embodiments, the concentration of base is from about 0.00001 M to about 0.5 M. In some embodiments, the concentration of base is from about 0.1 M to about 0.25 M. In some embodiments, the concentration of base is about 0.2 M.
  • a suitable base such as Na 2 C0 3 or NaOH
  • the concentration of hyaluronic acid used during the cross-linking contributes to the quality of the compositions comprising cross-linked hyaluronic acid, and ultimately improves certain properties of threads that are prepared from such compositions.
  • the gels become increasingly firm when the concentration of hyaluronic acid used during cross-linking is at least about 5%.
  • the gel swelling ratio in water can be increased by decreasing the concentration of hyaluronic acid used during the cross-linking.
  • the composition during the cross-linking comprises from about 1 weight % to about 25 weight % hyaluronic acid, before cross-linking.
  • the composition during the cross-linking comprises about 14 weight % hyaluronic acid, before cross-linking. In another embodiment, the composition during the cross-linking comprises about 12 weight % hyaluronic acid, before cross-linking. In another embodiment, the composition during the cross-linking comprises about 8 weight % hyaluronic acid, before cross-linking. In another embodiment, the composition during the cross-linking comprises about 5 weight % hyaluronic acid, before cross-linking.
  • the cross-linking is performed neat, i.e., without a solvent. Therefore, in certain embodiments, neat BDDE is contacted with dry hyaluronic acid to provide the cross-linked hyaluronic acid. The composition can then be hydrated with the desired amount of aqueous medium to provide the gel composition.
  • compositions comprising cross-linked hyaluronic acid are formed when hyaluronic acid is contacted with a cross-linking agent.
  • the cross-linking agent to be used in the present disclosure should comprise complimentary functional groups to that of hyaluronic acid such that the cross- linking reaction can proceed.
  • the cross-linking agent can be homobifunctional or heterobifunctional. It is contemplated that the percent hydration of the thread may be at least partially controlled by the type of cross-linking agent employed. For example, if the cross-linking leaves the carboxyl groups of the hyaluronic acid unfunctionalized, the percent hydration of the thread may be higher than esterified hyaluronic acid.
  • Suitable cross-linking agents include, but are not limited to, butanediol diglycidyl ether (BDDE), divinyl sulfone (DVS), and l-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC), or a combination thereof.
  • BDDE butanediol diglycidyl ether
  • DVS divinyl sulfone
  • EDC l-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride
  • the concentration of cross-linking agent, e.g., BDDE, used during cross-linking contributes to the quality of the compositions comprising cross-linked hyaluronic acid and, ultimately, to improve certain properties of the threads that are prepared from such compositions.
  • the amount of BDDE used is sufficient to produce a composition comprising at least 15 mole % of a BDDE derivative relative to the repeating disaccharide unit of the hyaluronic acid.
  • the composition comprises from about 15 mole % to about 25% mole percent, or about 17 mole % to about 20 mole % of the BDDE derivative, or about 18 mole % to about 19 mole %.
  • the composition comprises 18.75% of the BDDE derivative.
  • the amount of BDDE selected will be sufficient enough to provide a firm composition.
  • the gels become increasingly firm when the concentration of BDDE used during cross- linking is at least about 10 weight % relative to the weight of the hyaluronic acid.
  • the amount of BDDE used during cross-linking, upon formation of the composition comprising cross-linked hyaluronic acid, may also be expressed as a weight % relative to the weight of the hyaluronic acid used during cross-linking. In one embodiment, between 25 weight % and 100 weight % BDDE is used relative to the weight of hyaluronic acid. In another embodiment, at least 30% BDDE is used relative to the weight of hyaluronic acid.
  • about 30% BDDE is used relative to the weight of hyaluronic acid. In another embodiment, at least 40% BDDE is used relative to the weight of hyaluronic acid. In another embodiment, about 40% BDDE is used relative to the weight of hyaluronic acid. In another embodiment, at least 50% BDDE is used relative to the weight of hyaluronic acid. In another embodiment, about 50% BDDE is used relative to the weight of hyaluronic acid. In another embodiment, between about 50% BDDE and about 75% BDDE is used relative to the weight of hyaluronic acid. In another embodiment, between about 75% BDDE and about 100% BDDE is used relative to the weight of hyaluronic acid.
  • hyaluronic acid is cross-linked or covalently modified to form
  • compositions comprising substantially cross-linked hyaluronic acid.
  • the amount of cross-linking agent incorporated therein, or cross-link density should be sufficiently high such that the thread formed thereby is elastomeric, however it should not be so high that the resulting thread becomes too rigid such that it cannot be moved within the skin during delivery when used as a soft tissue augmentation product.
  • the appropriate stiffness or elastic modulus is determined by the intended use of the thread.
  • any excess cross-linking agent can be washed away.
  • Water rinsing alone is typically insufficient to remove all excess cross-linking agent.
  • Water rinsing can also be followed with or replaced by rinsing with a buffer and/or alcohol solvent, such as ethanol to remove the unreacted BDDE. It is contemplated that multiple washings may be necessary to remove all or substantially all of the excess cross-linking agent. It is further contemplated that the gels may be cut into smaller pieces or extruded from a syringe to improve the efficiency of the washing steps.
  • the hydrated or washed gel pieces have been sized.
  • the sizing may be accomplished by loading the gel into a syringe and extruding through a needle (typically a 20 gauge (G) blunt needle) or through a screen (e.g., 355 ⁇ screen). More than one or even a series of sizing steps can be performed using the same or a different, typically a smaller, gauge needle or screen than the previous sizing step.
  • the gel can be first extruded through a 20G needle once or twice, and then optionally extruded through a 23G or a 25G needle one or more times. The more sizing steps implemented, the smoother the resultant thread.
  • Thread swell ratio does not change substantially with increased sizing (between 1.66 and 1.70 for one, two and three sizing steps), although the dry diameter of the thread decreases slightly with increased sizing.
  • the compositions comprising cross-linked hyaluronic acid, as described above are substantially dried (e.g., dehydrated) before being further combined with binder.
  • the aqueous gel compositions comprising cross-linked hyaluronic acid, as described above are substantially dried (e.g., dehydrated) before being further combined with noncross-linked hyaluronic acid.
  • drying is accomplished by air-drying or first decanting the solvent before air drying at ambient or elevated temperatures.
  • drying is accomplished by lyophilization.
  • drying is partial.
  • the compositions comprising cross-linked hyaluronic acid, as described above are isolated via precipitation from a suitable solvent, such as ethanol, before being further combined with binder.
  • the precipitation can be implemented multiple, i.e., more than one, time.
  • the particle size of the gel isolated via precipitation are substantially the same size as, or smaller than, the particles of the lyophilized gel.
  • the threads made from the gel isolated via precipitation have a small dried thread diameter (e.g., about 0.014"-0.015"), yet exhibit a faster rate of swelling, enhanced softness and larger swell diameter.
  • the aqueous gel composition comprising cross-linked hyaluronic acid is dehydrated to remove about 25% of the water content by weight. In one embodiment, the aqueous gel composition comprising cross-linked hyaluronic acid is dehydrated to remove about 50% of the water content by weight. In one embodiment, the aqueous gel composition comprising cross-linked hyaluronic acid is dehydrated to remove about 75% of the water content by weight. In one embodiment, the aqueous gel composition comprising cross-linked hyaluronic acid is dehydrated to remove about 90% of the water content by weight.
  • the dried cross-linked hyaluronic acid composition as described above, can be combined with water to form a substantially cross-linked hyaluronic acid gel, which can then optionally be formulated with a binder (e.g., noncross-linked hyaluronic acid) and/or additive (e.g., a salt, excipient, lidocaine, or the like).
  • a binder e.g., noncross-linked hyaluronic acid
  • additive e.g., a salt, excipient, lidocaine, or the like.
  • the resulting formulated gel composition comprising cross-linked hyaluronic acid, and optional binder such as noncross-linked hyaluronic acid, can then be extruded into a wet thread which can then be dried.
  • the cross-linked hyaluronic acid is present in the composition, before thread drying and optionally with a binder such as noncross-linked hyaluronic acid, in an amount of from about 5 weight % to about 20 weight % based on the total weight of the composition.
  • the cross-linked hyaluronic acid is present in the composition, before thread drying and optionally with a binder such as noncross-linked hyaluronic acid, in an amount of from about 5 weight % to about 12 weight % or about 8 weight % to about 10 weight % based on the total weight of the composition, excluding moisture.
  • a composition comprising the substantially cross- linked hyaluronic acid of any of the above embodiments, that has been dried and rehydrated, and further comprises a binder.
  • the binder is noncross-linked hyaluronic acid.
  • the binder, such as noncross-linked hyaluronic acid is provided as an aqueous solution.
  • the binder, such as noncross-linked hyaluronic acid is provided as an aqueous solution further comprising a salt, such as CaCl 2 .
  • the binder such as noncross- linked hyaluronic acid
  • the binder is provided as an aqueous solution further comprising 1 mM CaCl 2 , 2.5 mM CaCl 2 , 10 mM CaCl 2 , or greater than 10 mM CaCl 2 .
  • the quality of the dry threads as described herein is dependent, at least partially, upon the quantity of the total hyaluronic acid solids used to make the wet thread compositions, as described above.
  • the "hyaluronic acid solids" include any combination of substantially cross-linked hyaluronic acid and/or noncross-linked hyaluronic acid (i.e., binder).
  • a minimum quantity of hyaluronic acid solids contributes to the quality of the dry threads, for example, by supporting the cross-sectional shape (e.g., relatively round diameter) of the wet threads used to make the dry threads.
  • a minimum quantity of hyaluronic acid solids may further contribute to the quality of the dry threads, for example, by increasing the tensile strength of the dry threads and/or the swelling ratio by which the dry threads absorb water.
  • a minimum quantity of hyaluronic acid solids may contribute still further to the quality of the dry threads by increasing the smoothness of the dry threads. Exemplary minimum quantities of hyaluronic acid solids are described below.
  • the wet thread comprises from about 2% to about 50% hyaluronic acid solids. In one embodiment, the wet thread comprises from about 2% to about 40% hyaluronic acid solids. In one embodiment, the wet thread comprises from about 2% to about 20% hyaluronic acid solids.
  • the wet thread comprises at least 7% hyaluronic acid solids. In one embodiment, the wet thread comprises at least 10% hyaluronic acid solids. In one embodiment, the wet thread comprises at least 12% hyaluronic acid solids. In one embodiment, the wet thread comprises at least 15% hyaluronic acid solids. In one embodiment, the wet thread comprises at least 18% hyaluronic acid solids. In one embodiment, the wet thread comprises at least 20% hyaluronic acid solids. In one embodiment, the wet thread comprises at least 25% hyaluronic acid solids.
  • the hyaluronic acid solids that are used to make the wet and dry threads as described herein can include any combination of cross-linked hyaluronic acid and/or noncross- linked hyaluronic acid (i.e., binder).
  • Adjustments in the quantity and/or ratio of cross-linked hyaluronic acid and/or noncross-linked hyaluronic acids can improve certain properties of the threads (e.g., the cross-sectional shape of the wet threads, the tensile strength of the dry threads, the swelling ratio by which the dry threads absorb water, the smoothness of the dry threads, the resistance of the dry threads to in vitro enzymatic digestion by hyaluronidase, and/or an increased in vivo half-life).
  • the cross-linked hyaluronic acid is present in compositions used to make threads in an amount of from about 1 weight % to about 25 weight % based on the total weight of the composition. In another embodiment, the cross-linked hyaluronic acid is present in an amount of from about 2 weight % to about 15 weight % based on the total weight of the composition. In another embodiment, the cross-linked hyaluronic acid is present in an about 14 weight %. In another embodiment, the cross-linked hyaluronic acid is present in an about 12 weight %. In another embodiment, the cross-linked hyaluronic acid is present in an about 8 weight %. In another embodiment, the cross-linked hyaluronic acid is present in an about 5 weight %.
  • the noncross-linked hyaluronic acid is present in compositions used to make threads in an amount of from about 1 weight % to about 20 weight % based on the total weight of the composition. In another embodiment, the noncross-linked hyaluronic acid is present in an amount of from about 1 weight % to about 8 weight % based on the total weight of the composition. In another embodiment, the noncross-linked hyaluronic acid is present in an amount of about 5 weight %. In another embodiment, the noncross-linked hyaluronic acid is present in an amount of about 3 weight %. In another embodiment, the noncross-linked hyaluronic acid is present in an amount of about 2 weight %.
  • the compositions used to make threads comprise from about 5 weight % to about 15 weight % cross-linked hyaluronic acid and from about 2 weight % to about 8 weight % noncross-linked hyaluronic acid. In one embodiment, the composition comprises about 12 weight % cross-linked hyaluronic acid and about 3 weight % noncross-linked hyaluronic acid. In one embodiment, the composition comprises about 8 weight % cross-linked hyaluronic acid and about 2 weight % noncross-linked hyaluronic acid. In one embodiment, the composition comprises about 5 weight % cross-linked hyaluronic acid and about 5 weight % noncross-linked hyaluronic acid.
  • compositions used to make threads can be made with higher or lower concentrations of HA and cross-linked HA; the above three compositions are given as examples only.
  • the aqueous gel composition comprising cross-linked and noncross- linked hyaluronic acid is deaerated (i.e., degassed), prior to extrusion to minimize air bubbles after extrusion.
  • degassing can also be done by using a syringe. It has been discovered that the tensile strength of threads generally improves upon deaeration of the compositions used to make the threads.
  • the compositions used to make the threads are deaerated at least once. In some embodiments, the compositions used to make the threads are deaerated more than once. In some embodiments, the compositions used to make the threads are deaerated between two and ten times. In some embodiments, the compositions used to make the threads are deaerated twice. In some embodiments, the compositions used to make the threads are deaerated three times, four, five, six, seven, eight, nine, or ten times. In some embodiments, the compositions used to make the threads are deaerated at least ten times.
  • the aqueous gel composition comprising cross-linked and noncross- linked hyaluronic acid is typically extruded onto a substrate, as described below, to form a wet thread.
  • the composition is extruded using a pressurized syringe affixed to a nozzle.
  • the nozzle can have various geometries, such as various lengths, internal diameters and shapes.
  • the properties of the dry thread compositions can be improved by increased nozzle size (e.g., width) during extrusion of the wet thread.
  • improved properties in the threads can include, for example, the cross-sectional shape of the threads, the tensile strength of the threads, the swelling ratio by which the threads absorb water, the smoothness of the threads, the resistance of the dry threads to in vitro enzymatic digestion by hyaluronidase, and/or an increased in vivo half-life of the dry threads.
  • the nozzle may be circular or non-circular in shape, for example, a flattened shape or a "D" shape.
  • the syringe nozzle may be anywhere from about a 15 gauge to a 25 gauge syringe nozzle. In some embodiments, the syringe nozzle is a 15 gauge nozzle, whereas in other embodiments the syringe nozzle is a 16 gauge nozzle. In some embodiments, the syringe nozzle is a 17 gauge nozzle, whereas in other embodiments the syringe nozzle is a 18 gauge nozzle.
  • the syringe nozzle is a 19 gauge nozzle, whereas in other embodiments the syringe nozzle is a 20 gauge nozzle. In some embodiments, the syringe nozzle is a 21 gauge nozzle, whereas in other embodiments the syringe nozzle is a 22 gauge nozzle.
  • the pressure employed is from about 10 to about 2000 psi or from about 20 to about 240 psi. The pressure requirements are dictated by the nozzle geometry and other attributes such as consistency of the composition and desired flow rate.
  • the pressure can be applied pneumatically, for example using ambient air or nitrogen, hydraulically, or mechanically.
  • the speed at which the gel is extruded takes into consideration minimization of air bubbles in the length of the thread and maximization of a consistent uniform shape. Air bubbles can reduce the structural integrity of the thread by causing weak spots.
  • Pneumatic pressure and plate speed are not fixed but are instead adjusted and monitored in- process so that the gel is extruded in a continuous, linear manner.
  • the pneumatic pressure is first increased to the point of consistent but controllable gel flow.
  • the plate speed is then continuously fine-tuned so that threads are extruded in a uniform linear manner. If the plate speed is too slow zig-zagged threads may result; too fast and threads may stretch leading to necking and/or breakage.
  • Substrates include by hydrophilic and hydrophobic substrates and may be selected from, but are not limited to, polytetrafluoroethylene (PTFE), expanded PTFE, nylon, polyethylene terephthalate (PET), polystyrene, silicon, polyurethane, and activated cellulose.
  • PTFE polytetrafluoroethylene
  • PET polyethylene terephthalate
  • polystyrene polystyrene
  • silicon silicon
  • polyurethane polyurethane
  • activated cellulose activated cellulose
  • the substrate employed, along with the viscosity of the gel composition, dictates the general shape of the thread.
  • the thread formed could be substantially ribbon-shaped.
  • the thread formed could be substantially D-shaped. Still further, if the gel and the substrate have an equilibrium contact angle of greater than 90 degrees, then the thread formed could be substantially round.
  • a 10% 1.5 MDa gel will have a substantially circular cross-section (e.g., about 80% of a circle) when extruded on PTFE, while a 5% 1.5 MDa gel will form a flat ribbon when extruded on PTFE.
  • the gel composition can be rolled out into an elongated cylinder and/or cut into elongated strips before drying.
  • the wet thread is then dried to form a dry thread. Drying may be conducted under static conditions or, alternatively, with the assistance of a dynamic air flow (i.e., within a laminar flow hood). In some embodiments, yields of the threads improve with static drying.
  • the drying step is required to form threads with a sufficient tensile strength, as discussed below. As the thread may lose some of its properties when exposed to heat in excess of water boiling temperature, it is preferred that the drying step be performed under ambient conditions. This drying procedure provides a thread with a higher tensile strength, such as, for example, an ultimate tensile strength of about 5 kpsi to 100 kpsi or 20 kpsi to 80 kpsi. In other words, the threads as described herein have a failure load of at least about 0.1 pounds or 0.22 kilograms.
  • the thread is allowed to dry for anywhere from about 30 minutes to about 72 hours to form threads having a diameter of from 0.05 mm to about 1.0 mm and having 10%-30% by weight hydration.
  • the thread can be dried for about 12 hours or about 24 hours. It is contemplated that the larger the molecular weight of HA employed or the more concentrated the HA in the composition, the longer the drying times that are required.
  • a non-thermal stimulus such UV light, radiation, or a chemical initiator or a catalyst, may be employed to assist in the cross-linking reaction.
  • the thread is washed with an aqueous or non-aqueous solvent, a gas or a supercritical fluid.
  • this washing removes excess cross-linking agent.
  • the washing can be accomplished by a variety of methods, such as submersion in an aqueous solvent or by using a concurrent flow system by placing the thread in a trough at an incline and allowing an aqueous solvent to flow over the thread. Threads can also be suspended, for example vertically, and washed by dripping or flowing water down the length of the thread.
  • water is used to wash the threads.
  • the water not only washes the threads to remove excess cross-linking agent, it also rehydrates the thread into a hydrated elastomeric state.
  • an antioxidant solution is used to wash the threads.
  • a buffer solution comprising ascorbic acid, vitamin E and/or sodium phosphate is used to wash the threads.
  • a buffer solution comprising about 1 mM, or about 10 mM or about 100 mM, or about 1 M ascorbic acid is used to wash the threads.
  • the percent hydration of hyaluronic acid can range from about 1% to greater than about 1000% based on the total weight.
  • the percent hydration of the thread of the present disclosure can be controlled by adjusting the percent hyaluronic acid in the gel and/or controlling the amount and type of cross-linking agent added. It is contemplated that a lower percent hydration thread would result in a thread with a higher tensile strength. In some embodiments, the thread has no more than about 30% percent, or no more than 15%, or no more than 10% by weight hydration based on the total weight. The percent hydration will be determined by the environment to which the thread is subjected to during or after the drying process.
  • the half-life of the hyaluronic acid thread in vivo can be controlled by controlling the thickness of the thread, the density, the degree of cross-linking, the molecular weight of the hyaluronic acid and the degree of hydration, which can then be further controlled by adjusting the amounts of hyaluronic acid and cross-linking agent both individually and relatively. It is contemplated that the threads disclosed herein can have an enhanced half-life in vivo of from about 1 month to up to about 12 months as compared to less than 1 day for natural hyaluronic acid. In certain embodiments, it is contemplated that the threads described herein have an in vivo half-life of at least 1 month.
  • the threads described herein have an in vivo half-life of at least 2 months. In certain embodiments, it is contemplated that the threads described herein have an in vivo half-life of at least 3 months. In certain embodiments, it is contemplated that the threads described herein have an in vivo half-life of at least 4 months. In certain embodiments, it is contemplated that the threads described herein have an in vivo half-life of at least 6 months. In certain embodiments, it is contemplated that the threads described herein have an in vivo half-life of at least 8 months. In certain embodiments, it is contemplated that the threads described herein have an in vivo half- life of at least 10 months.
  • the threads described herein have an in vivo half- life of at least 12 months. In certain embodiments, it is contemplated that the threads described herein have an in vivo half- life of at least 14 months. In certain embodiments, it is contemplated that the threads described herein have an in vivo half-life of at least 16 months. In certain embodiments, it is contemplated that the threads described herein have an in vivo half- life of at least 18 months.
  • the threads described herein can be sterilized using typical sterilization methods known in the art, such as autoclave, ethyleneoxide, electron beam (e-beam), supercritical CO 2 (with peroxide), etc.
  • typical sterilization methods such as autoclave, ethyleneoxide, electron beam (e-beam), supercritical CO 2 (with peroxide), etc.
  • the threads as described herein can be sterilized using electron beam (e-beam) sterilization methods.
  • the threads are first washed in a buffer solution at high pH (i.e., pH 9 or pH 10).
  • the wash solutions further comprise ethanol, ascorbic acid, vitamin E and/or sodium phosphate.
  • the thread is mechanically stretched while hydrated, either soon after being hydrated or gradually before the first drying or after the rehydrating.
  • the stretching or absence of stretching can provide a thread of the desired length and/or rehydration swelling volume.
  • the length of the thread can be from about 0.5 cm to about 15 cm. In another embodiment, the length of the thread can be from about 2 cm to about 12 cm. In another
  • the length of the thread can be from about 5 cm to about 20 cm.
  • the thread After the thread is rehydrated it is allowed to dry again under ambient conditions for from anywhere from 30 minutes to about 72 hours. Upon drying, the thread, in some embodiments, cures to provide a more uniform surface of the thread.
  • This washing hydration/dehydration step can be performed multiple times to allow excess unreacted reagent to be washed from the thread or to continue to improve the degree of cross-linking or covalent modification. This is an improvement over methods such as the use of organic solvents to remove excess BDDE. 3. Thread Nomenclature
  • Threads as described herein are prepared from compositions comprising substantially cross- linked hyaluronic acid.
  • threads are prepared from compositions comprising substantially cross-linked hyaluronic acid, and further comprising a binder such as noncross-linked hyaluronic acid. Threads can be described according to the following nomenclature
  • AA/BB@XX/YY wherein AA/BB describes the initially formed composition comprising substantially cross-linked hyaluronic acid and XX/YY describes the composition with a binder, such as noncross-linked hyaluronic acid.
  • a thread referred to as "10/40@15/20” refers to a composition of substantially cross-linked hyaluronic acid, wherein the cross-linking reaction is performed with 10 weight % hyaluronic acid relative to the weight of the solution (e.g., an aqueous solution), using 40 weight % cross-linker (e.g., BDDE) relative to the weight of the hyaluronic acid.
  • the solution e.g., an aqueous solution
  • 40 weight % cross-linker e.g., BDDE
  • AA of AA/BB@XX/YY is at least 2%. In some embodiments, AA is at least 5%. In some embodiments, AA is about 8%. In some embodiments, AA is about 10%. In some embodiments, AA is at least 10%. In some embodiments, AA is about 12%. In some embodiments, AA is at least 15%.
  • BB of AA/BB@XX/YY is at least 10%. In some embodiments, BB is at least 20%. In some embodiments, BB is at least 30%. In some embodiments, BB is about 30%. In some embodiments, is at least 40%. In some embodiments, BB is about 40%. In some embodiments, BB is at least 50%. In some embodiments, BB is about 50%.
  • AA/BB of AA/BB@XX YY is about 8/10. In some embodiments, AA/BB is at least or about or exactly 8/20. In some embodiments, AA/BB is about 8/30. In some embodiments, AA/BB is about 8/40. In some embodiments, AA/BB is about 8/50. In some embodiments, AA/BB is about 10/10. In some embodiments, AA/BB is about 10/20. In some embodiments, AA/BB is about 10/30. In some embodiments, AA/BB is about 10/40. In some embodiments, AA/BB is about 10/50.
  • one or more binding agents such as noncross-linked hyaluronic acid, are added to the compositions comprising cross-linked hyaluronic acid, and the resulting compositions are converted by additional methods described herein to provide novel threads.
  • binding agents such as noncross-linked hyaluronic acid
  • the compositions comprising cross-linked hyaluronic acid further comprise noncross- linked hyaluronic acid.
  • the added noncross-linked hyaluronic acid is optionally referred to herein as a "binder.”
  • the combination of cross-linked hyaluronic acid and noncross-linked hyaluronic acid, within the composition, is optionally referred to herein as "hyaluronic acid solids.”
  • the XX of AA/BB@XX YY refers to the weight % of total hyaluronic acid solids relative to the weight of the composition, wherein the hyaluronic acid solids includes both the substantially cross-linked hyaluronic acid and any noncross-linked hyaluronic acid.
  • the YY of AA/BB@XX/YY refers to the weight % of noncross-linked hyaluronic acid relative to the weight of total hyaluronic acid solids.
  • XX of AA/BB@XX/YY is at least 2%. In some embodiments, XX is at least 5%. In some embodiments, XX is at least 10%. In some embodiments, XX is about 10%. In some embodiments, XX is at least 15%. In some embodiments, XX is about 15%. In some embodiments, XX is at least 20%. In some embodiments, XX is about 20%. In some embodiments, XX is at least 25%. In some embodiments, XX is about 25%.
  • YY of AA/BB@XX/YY is at least 5%. In some embodiments, YY is at least 10%. In some embodiments, YY is at least 20%. In some embodiments, YY is about 20%. In some embodiments, YY is at least 30%. In some embodiments, YY is about 30%. In some embodiments, YY is at least 40%. In some embodiments, YY is about 40%. In some embodiments, YY is at least 50%. In some embodiments, YY is about 50%.
  • AA/BB@XX/YY is 8/10@2/5, 8/20@5/10, 8/30@10/20,
  • threads comprising substantially cross-linked hyaluronic acid, wherein the hyaluronic acid is substantially cross-linked with at least about 15 mole % of a butanediol diglycidyl ether (BDDE) derivative relative to the repeating disaccharide unit of the hyaluronic acid, and at least about 5% noncross-linked hyaluronic acid relative to the weight of total hyaluronic acid solids, wherein the cross-linked hyaluronic acid is present in an amount of from about 60 weight % to about 90 weight % based on the total weight of the thread excluding moisture and the noncross-linked hyaluronic acid is present in an amount of from about 10 weight % to about 40 weight % based on the total weight of the thread excluding moisture.
  • BDDE butanediol diglycidyl ether
  • a therapeutic agent include antibacterials, anesthetics, dyes for viewing placement in vivo, and the like.
  • a dry or hydrated thread is coated to alter the properties with a bioabsorbable biopolymer, such as collagen, PEG, PLGA or a phase transfer Pluronic which can be introduced as a liquid and which solidifies in vivo.
  • the thread can be coated to modulate the rate at which the thread is rehydrated.
  • the thread can be coated with a hydrophobic layer, such as a lipid. The thickness of the lipid layer can then be adjusted to achieve the desired rate of rehydration.
  • the thread can be coated with an aqueous composition of noncross-linked hyaluronic acid. This can be performed just prior to implantation of the thread to act as a lubricant. It is also contemplated that this coating with noncross-linked hyaluronic acid may slow the rate of hydration of the thread.
  • the thread is coated, either totally or in part, with the gel composition to form a layered material. Woven constructs, whether single layer or 3D, can be coated in their entirety to create weaves or meshes with altered physical properties from that of a free-woven mesh.
  • the threads as described herein can be braided, coiled, layered or woven.
  • braids may be formed from the threads described above.
  • a braid can be formed by intertwining three or more threads wherein each thread is functionally equivalent in zigzagging forward through the overlapping mass of the others.
  • the braids can be a flat, three-strand structure, or more complex braids can be constructed from an arbitrary (but usually odd) number of threads to create a wider range of structures, such as wider ribbon-like bands, hollow or solid cylindrical cords, or broad mats which resemble a rudimentary perpendicular weave.
  • a plasticizer is added to adjust the stiffness of the thread.
  • threads of varying stiffness may be weaved together to produce a braided thread or material having the desired stiffness.
  • a three-dimensional structure may be constructed by weaving or wrapping or coiling or layering the threads described above. In other embodiments, a three- dimensional structure may be constructed by weaving or wrapping or coiling or layering the braids described above. In still other embodiments, a three-dimensional structure may be constructed by weaving or wrapping or coiling or layering the cords described above. In still other embodiments, a three-dimensional structure may be constructed by weaving or wrapping or coiling or layering the meshes described above.
  • a three-dimensional, cylindrical implant is made of any of the threads is provided.
  • An exemplary use for such an implant is for nipple reconstruction.
  • the threads used to make the cylindrical implant are cross-linked and include chrondrocyte adhesion compounds.
  • the cylindrical shape is provided by multiple, concentric coils of threads. Thread Embodiments
  • the thread comprises (i) cross-linked hyaluronic acid wherein the cross linked hyaluronic acid has been cross linked with butanediol diglycidyl ether (BDDE), and (ii) non-cross linked hyaluronic acid.
  • BDDE butanediol diglycidyl ether
  • non-cross linked hyaluronic acid there is provided a dry thread comprising hyaluronic acid, wherein at least a portion of the hyaluronic acid is substantially cross-linked with at least about 15 mole % of a BDDE derivative relative to the repeating disaccharide unit of the hyaluronic acid.
  • the substantially cross-linked hyaluronic acid is cross-linked with from about 15 mole % to about 20 mole % of the BDDE derivative. In one embodiment, the substantially cross- linked hyaluronic acid is cross-linked with from about 16 mole % to about 19 mole % of the BDDE derivative.
  • the cross-linked hyaluronic acid is present in an amount of from about 50 weight % to about 90 weight % based on the total weight of the dry thread. In another embodiment, the cross-linked hyaluronic acid is present in an amount of from about 60 weight % to about 80 weight % based on the total weight of the dry thread.
  • the dry thread further comprises a binder, such as for example, noncross-linked hyaluronic acid.
  • the noncross-linked hyaluronic acid may be present in an amount of from about 1 weight % to about 50 weight % based on the total weight of the dry thread. In one embodiment, the noncross-linked hyaluronic acid is present in an amount of from about 15 weight % to about 20 weight % based on the total weight of the dry thread.
  • the dry thread has an ultimate tensile strength of from about 2 kpsi to about 20 kpsi. In one embodiment, the thread has an ultimate tensile strength of from about 4 kpsi to about 10 kpsi.
  • the dry thread has a diameter of at least about 0.04 inches. In one embodiment, the dry thread has a diameter of from about 0.01 to about 0.08 inches.
  • the dry thread has a weight/length ratio from about 5 to about 15 mg/inch.
  • the dry thread has a failure load of about 0.3 pounds or greater. In another embodiment, the dry thread has a failure load of from about 0.3 to about 1.3 pounds.
  • the dry thread further comprises a needle.
  • a dry thread comprising substantially cross-linked hyaluronic acid prepared by the steps of: a) forming a substantially cross-linked hyaluronic acid composition by contacting hyaluronic acid with BDDE; b) adding noncross-linked hyaluronic acid to the substantially cross-linked hyaluronic acid composition; c) extruding the substantially cross-linked hyaluronic acid composition to form a wet thread; and d) drying the wet thread to form a dry thread.
  • from about 5 to about 15 weight % hyaluronic acid is contacted with from about 2 to about 8 weight % BDDE relative to the weight of the hyaluronic acid.
  • the hyaluronic acid is contacted with about 40 weight % BDDE relative to the weight of the hyaluronic acid.
  • the cross-linked hyaluronic acid is cross-linked with at least about 15 mole % of a BDDE derivative relative to the repeating disaccharide unit of the hyaluronic acid.
  • the cross-linked hyaluronic acid is cross-linked with from about 15 to about 25 mole % of the BDDE derivative relative to the repeating disaccharide unit of the hyaluronic acid. In one embodiment, the cross-linked hyaluronic acid is cross-linked with from about 17 to about 20 mole % of the BDDE derivative relative to the repeating disaccharide unit of the hyaluronic acid. In another embodiment, the cross-linked hyaluronic acid is cross-linked with at least about 12 weight % of the BDDE derivative relative to the weight of the hyaluronic acid.
  • At least 5% hyaluronic acid is contacted with from about 2 to about 8 weight % BDDE relative to the weight of the hyaluronic acid composition. In another embodiment, about 8% hyaluronic acid is contacted with from about 2 to about 8 weight % BDDE relative to the weight of the hyaluronic acid composition. In one embodiment, about 10% hyaluronic acid is contacted with from about 2 to about 8 weight % BDDE relative to the weight of the hyaluronic acid composition.
  • the composition formed by contacting hyaluronic acid with BDDE comprises cross-linked hyaluronic acid in an amount of from about 1 weight % to about 50 weight % hyaluronic acid based on the total weight of the composition. In one embodiment, the composition formed by contacting hyaluronic acid with BDDE comprises cross-linked hyaluronic acid in an amount of from about 5 weight % to about 20 weight % hyaluronic acid based on the total weight of the composition. In another embodiment, the dry thread further comprises drying the composition formed by contacting hyaluronic acid with BDDE.
  • from about 1 weight % to about 50 weight % noncross-linked hyaluronic acid is added, based on the total weight of the composition.
  • from about 2 weight % to about 15 weight % noncross-linked hyaluronic acid is added, based on the total weight of the composition.
  • about 3 weight % noncross-linked hyaluronic acid is added, based on the total weight of the composition.
  • the dry thread has an ultimate tensile strength of from about 2 kpsi to about 20 kpsi. In one embodiment, the dry thread has an ultimate tensile strength of about 20 kpsi or greater.
  • the dry thread has a failure load of about 0.3 pounds or greater. In one embodiment, the thread has a failure load of from about 0.3 to about 1.3 pounds. [0138] In one embodiment, there is provided a thread according to any of the above embodiments, wherein the thread is terminally sterilized.
  • the threads, braids, cords, woven meshes or three-dimensional structures described herein can be used for treating striae.
  • Striae or the more commonly known term, stretch marks, are a form of scarring on the skin caused by tearing of the dermis. Stretch marks are often the result of rapid stretching of the skin associated with rapid growth or rapid weight changes.
  • a method of treating a stria in a patient in need thereof comprising; a) inserting a thread into skin or subcutaneous space of the patient adjacent to or under the stria; and b) applying the thread adjacent to or under the stria, thereby treating the stria, wherein the thread comprises cross-linked hyaluronic acid.
  • steps can be performed at least once and up to 6 times to treat each stria.
  • the thread comprises substantially cross-linked hyaluronic acid.
  • the thread comprises (i) cross-linked hyaluronic acid wherein the cross linked hyaluronic acid has been cross linked with butanediol diglycidyl ether (BDDE), and (ii) non-cross linked hyaluronic acid.
  • the hyaluronic acid is substantially cross-linked with at least about 15 mole % of a butanediol diglycidyl ether (BDDE) derivative relative to the repeating disaccharide unit of the hyaluronic acid, and at least about 5% noncross-linked hyaluronic acid relative to the weight of total hyaluronic acid solids.
  • BDDE butanediol diglycidyl ether
  • Example 1 Treatment of striae with the HA threads disclosed herein is described in Example 1 1.
  • the thread is attached to the proximal end of a needle as shown in Figs. 2, 3A and 3B.
  • the thread is inserted by a needle which needle is then removed.
  • the thread is hydrated with water or saline, or by the fluids normally perfusing the surrounding tissue.
  • the remainder of the stria can be filled with a biocompatible material such as a phase transfer PluronicTM which can be introduced as a liquid and which solidifies in vivo.
  • PluronicTM phase transfer PluronicTM
  • conventional hyaluronic acid gel can be introduced to fill the stria. In either case, the formed web acts to maintain the biocompatible filler at the site of the stria.
  • the attending clinician may numb the treatment area according to procedures known in the art using a variety of anesthetics, including, but not limited to, topical lidocaine, ice or a block with lidocaine injection.
  • the thread may be attached to a needle as illustrated, for example, in Figs. 2, 3A and 3B.
  • the distal end of the needle may be inserted through the skin surface of the subject into the dermis adjacent to or within the stria.
  • the thread is inserted into the subcutaneous space instead of the dermis.
  • the needle then may traverse the dermis or subcutaneous space of the subject beneath the stria.
  • the needle then may exit the skin of the subject at the opposite margin of the stria.
  • the needle may then be pulled distally until it is removed from the subject such that the thread is pulled into the location previously occupied by the needle beneath the stria. Finally, excess thread is cut from the needle at the skin surface of the subject which leaves the thread implanted.
  • the thread is manipulated in such a fashion such that one end of the thread is sufficiently hard such that the thread is used to penetrate the skin. This may be
  • the thread is coated with a hardening material, such as a sugar coating.
  • a hardening material such as a sugar coating.
  • the thread is coated in its entirety, for example with a sugar coating, to provide the thread with increased columnar strength.
  • any number of threads may be used depending on the desired effect and the size of the thread.
  • the threads may be implanted in various tissue planes of the patient to provide a more natural look when treating striae.
  • the threads may be implanted in a manner that forms a hammock in the desired location.
  • the attending clinician may deposit or implant the threads in the epidermis, the dermis, and/or the subcutaneous layer.
  • the threads may be placed deeply, for example in the subcutaneous space, near a stria, which may help soften the appearance of the stria.
  • the thread can be placed superficially, for example within the dermis.
  • threads can also be implanted in a hatch and/or cross-hatch pattern to effect areas greater than the width of a single thread.
  • the cross-hatching could be done obliquely to the initial direction or perpendicularly.
  • the hatches can be in different tissue planes as well.
  • the hatching can be done obliquely to the directionality of the area being treated.
  • the method can further comprise the administration of an additional therapy for the treatment of striae.
  • prevention therapies such as topical creams, oils, and/or lotions may be combined with the treatment using HA threads as described herein.
  • Other suitable combination treatments include, for example, creams comprising Golu Kola extract, vitamin E, panthenol, elastin, hyaluronic acid, and methanol, oils such as egg oil, lotions or creams comprising cocoa butter, and treatments for improving the appearance of existing stretch marks such as, for example, laser treatments, fractional laser resurfacing, dermabrasion, and prescription retinoids.
  • the additional therapy may coincide with the treatment of striae using HA threads, or the additional therapy may occur prior to or after the HA thread treatment.
  • Cross-linked hyaluronic acid threads can be made according to the following procedures.
  • Cross-Unking preparation of cross-linked hyaluronic acid gel
  • Hyaluronic acid (HA) powder is hydrated in about 75% of a desired total volume of NaOH for about 30 minutes at about 50 °C in an appropriate container.
  • the hydrated HA is then added to a syringe and mixed thoroughly (e.g., syringe-to-syringe about 20 times). Heating is continued for approximately 30 minutes.
  • Cross-linker e.g., BDDE
  • BDDE hydrated hyaluronic acid solution
  • heated for about 30 minutes re-mixed (e.g., syringe-to-syringe about 20 times)
  • Heating is then continued at about 50 °C for an additional 3 to 5 hours.
  • HA molecular weight (MDa) e.g., 0.7, 1.7, 2.7.
  • HA hydration time e.g., 0 minutes, 30 minutes, 1 hour, 2 hours, overnight.
  • HA concentration (% w/w HA:aqueous NaOH): e.g., 5, 6, 7, 8, 9, 10, 1 1, 12.
  • BDDE concentration e.g., 0.5, 2, 2.5, 5, 7.5, 8, 10, 20, 30, 40, 100.
  • the cross-linked hyaluronic acid gel is rinsed to remove the sodium hydroxide and any unreacted BDDE. Water can also be removed, and the gels may be fragmented to facilitate the extrusion step and/or for rinsing efficiency. In such an instance, sizing is accomplished by cutting the gel into approximately 0.5 cm cubes. Rinsing is then achieved by rinsing with about 40 volumes of 10 mM sodium phosphate, at pH 6.0, three times for about 30 minutes each, rinsing with 100% ethanol six times for about 30 minutes, and then rinsing with water four times for about 30 minutes.
  • the swollen gel pieces can then be further sized into approximately 0.25 cm cubes, loaded into a syringe, and extruded through a 20 gauge (G) blunt needle. More than one sizing step can be performed using the same or a different, typically smaller, gauge needle (e.g., 20G, then two 25G sizing steps).
  • the cross-linked hyaluronic acid gel is then diluted approximately 2: 1 with water, loaded into a pan dried. The drying is accomplished by air drying under ambient conditions or
  • the gel is isolated via precipitation from ethanol.
  • the gel is either partially dried to a desired final concentration or dried completely.
  • the completely dried cross-linked hyaluronic acid gel is formulated as an aqueous composition to the desired final HA concentration (e.g., 2.5%, 5%, 7.5%, 10%, 12.5%, 15%, 20%).
  • the partially dried cross-linked hyaluronic acid gel can be used as an aqueous composition in the formulation without further treatment.
  • the aqueous composition of cross-linked hyaluronic acid gel can then be further formulated with a binder such as noncross-linked hyaluronic acid.
  • a binder such as noncross-linked hyaluronic acid.
  • noncross-linked hyaluronic acid is hydrated (e.g., overnight at 4 °C) at the desired final HA concentration (e.g., 2.5%, 5%, 7.5%, 10%, 12.5%, 15%, 20%).
  • the binder is mixed with the cross-linked hyaluronic acid gel.
  • Typical binders include noncross-linked hyaluronic acid, salts (e.g., CaCl 2 ), excipients, Lidocane, and the like.
  • the aqueous composition can comprise any aqueous medium, such as an acid, a base, a buffer or a salt.
  • Buffers such as phosphate buffered saline can be used (e.g., 10 mM PBS at pH 7.4).
  • Calcium chloride solutions can also be used (e.g., 1 mM, 2.5 mM, or 5 mM).
  • Sodium hydroxide (NaOH) solutions may be used, (e.g., 0.1M, 0.2M, 0.3M, or 0.5M).
  • compositions can be made with higher or lower concentrations of hyaluronic acid and cross- linked HA; the following three compositions are given as examples only.
  • the final extruded composition contained 12% (w/w) cross- linked hyaluronic acid and 3% (w/w) noncross-linked HA, wherein the cross-linked hyaluronic acid was derived from a cross-linking reaction with either 10% hyaluronic acid and 4% BDDE, or 8% hyaluronic acid and 3.2% BDDE.
  • the final extruded composition contained 8% (w/w) cross-linked hyaluronic acid and 2% (w/w) noncross-linked HA, the cross-linked hyaluronic acid being derived from a cross-linking reaction with either 10% hyaluronic acid and 4% BDDE, or 8% hyaluronic acid and 3.2% BDDE.
  • the final extruded composition contained 5% (w/w) cross-linked hyaluronic acid and 5% (w/w) noncross-linked HA, the cross-linked hyaluronic acid being derived from a cross-linking reaction with 10% hyaluronic acid and 4% BDDE.
  • the final gel formulations are then extruded onto a suitable surface to yield wet threads.
  • Various nozzle sizes are used depending on the final desired thread thickness (e.g., 20G, 19G, 18G, 17G, 16G).
  • the final gel formulations are transferred to a pressurized extruder (e.g., EFD Model XL 1500 pneumatic dispense machine).
  • the nozzle of the extruder can have a tip ranging from a 15 gauge to about 25 gauge.
  • the syringe pressure may be between about 10 psi and about 2000 psi, depending on the viscosity of the final gel formulation. For very viscous gel formulations, a pressure multiplier can be used.
  • the wet thread was then formed by extruding the final gel formulation onto a substrate by an extruder to achieve the desired wet thread thickness.
  • an extruder For example, to achieve a similar dried diameter, one can use a 20 gauge needle for 15% hyaluronic acid compositions, or a 19 gauge needle for 10% hyaluronic acid compositions.
  • the wet thread can then be dried under ambient conditions to a percent hydration of less than about 30%, or less than about 15%, or less than about 10%, thus providing a dry thread.
  • the thread can be allowed to dry under a relative humidity of from about 20% to about 80% at a temperature of from about 20 °C to about 37 °C.
  • threads can be air-dried for two days at ambient conditions.
  • the wet thread prior to thread drying, can be stretched to a desired length and reduced diameter prior to dying.
  • the stretching can be by either hanging the thread by one end and applying weight to the opposing end, or by horizontally stretching the wet thread on a surface (either the same or different from the extrusion surface) and adhering the ends to the surface.
  • the dry threads can be attached to a needle using known techniques (see, e.g., Figs. 2, 3A and 3B). Sterilizing
  • the threads as described herein can be sterilized using electron beam (e-beam) sterilization methods. Threads as prepared in Example 1 cross-linked with BDDE were washed in a phosphate buffer or Tris buffer solution at pH 10. Some of the solutions further contained 1 mM ascorbic acid, 10 mM ascorbic acid, 100 mM ascorbic acid, 1 M ascorbic acid, 10 mM vitamin E, and 50 mM Na 3 P0 4 . The threads were then sterilized using standard e-beam techniques at 4 kGy or 20 kGy. In some embodiments, the temperature of the thread can be altered prior to sterilizing. In some embodiments, the temperature is reduced of the thread to about -20 °C. In some embodiments, the thread is just below 5 °C after sterilizing.
  • e-beam electron beam
  • threads can be prepared using any one of the processes disclosed below.
  • Threads can be prepared using the following steps:
  • Threads can also be prepared using the following steps
  • Threads can also be prepared using the following steps
  • Threads can also be prepared using the following steps
  • Threads can also be prepared using the following steps:
  • the dry threads can be washed with an aqueous solvent to remove any contaminants, such as unreacted cross-linking agent.
  • the washing can be performed by various methods, such as submersion in an aqueous solvent or by using a concurrent flow system by placing the thread in a trough at an incline and allowing an aqueous solvent to flow over the thread.
  • the thread once it is rehydrated, can be stretched prior to re-drying. The stretching can be performed by the means described above in Example 1.
  • the rehydrated and washed thread is then re-dried to provide the dry thread.
  • the re-drying is typically performed under ambient conditions (i.e.
  • the thread can be washed several times (e.g. 10 or more times) without losing its structural integrity. Over the course of multiple washing cycles the overall length of the thread can be increased by between about 25% to about 100%.
  • Sample threads prepared from the methods of Example 1 are provided in Table 1 below.
  • Thread density was determined by measuring the weight of a thread of a measured length and calculating the ratio of weight to length.
  • Dry thread circularity (W:T) and diameter (D) were determined by sectioning threads axially and measuring the shortest (W) and longest diameter (T) for a given cross-section. Circularity or aspect ratio is the ratio of W:T.
  • Thread diameter (D) is an average of short (W) and long (T) diameters.
  • the average elongation (in inches) for unsterilized threads made with 20G and 19G needles were from about 0.028 inches to about 0.192 inches.
  • the average elongation (in inches) for e-beam sterilized threads made with 20G, 19G and 18G needles were from about 0.021 inches to about 0.078 inches.
  • the average tensile strength (in psi) for unsterilized threads made with 20G and 19G needles were from about 3236 psi to about 19922 psi.
  • the average tensile strength (in psi) for e-beam sterilized threads made with 20G and 19G needles were from about 1943 psi to about 12859 psi.
  • the mass swelling ratio is the ratio of the swollen gel weight relative to the fully dried gel weight (Tables 2 and 3).
  • the diameter swelling ratio ratio of hydrated thread to dry thread of threads extruded from a 20G extrusion nozzle having an average dry thread diameter of 0.0132 inches was calculated. Each thread tested had a diameter swelling ratio of 1.5 or more, with the average diameter swelling ratio being 1.55.
  • Threads were incubated with hyaluronidase at 1 mg/mL in 1 mL of buffer (100 mM sodium acetate, pH 4.5, 150 mM NaCl) at 37 °C; control threads were are not in the presence of
  • hyaluronidase At various times, 40 ⁇ ⁇ aliquots of supernate were withdrawn and assayed by the Carbazole Assay (Cesaretti, M, et al., Carbohydrate Polymers 54: 59-61 (2003) for hyaluronic acid. Vertical arrows correspond to the addition of fresh 1 mg/mL of hyaluronidase. The supernates were replaced with fresh 1 mg/mL enzyme in buffer.
  • Tissue samples containing thread implants were fixed in an acid-formalin ethanol fixative before embedding in methyl methacrylate. Histological sections were stained with hematoxylin and eosin (H&E) as well as Alcian blue with neutral red to visualize cellular responses and implant presence, respectively. The 1 -month, 2-month, 3 -month, 6-month and 9-month histology images of 8/40 @ 15/20 formulation are shown in Fig. 5A, 5B, 5C, 5D, and 5E. The samples were similar in appearance indicating that the threads were persisting in vivo.
  • H&E hematoxylin and eosin
  • Thread formulations described herein were implanted in the dorsal dermis of New Zealand White rabbits and evaluated at 1-week, 1 -month, 2- month, 3-month, 6-month, and 9-month time points.
  • implant sites were evaluated for implant presence via palpation and a tactile scoring system (See Example 8).
  • animals were euthanized and implant sites harvested for gross and histological evaluation.
  • a subset of implant sites were cross-sectioned axially with a scalpel and evaluated under microscope for the visual presence of implant material in the dermal tissue.
  • Hypodermic needles 22 to 25 Ga can be affixed with single or double strands of hyaluronic acid threads (cross-linked with BDDE), ranging from thicknesses of 0.02 in to 0.08 in.
  • the samples can be e-beam sterilized by NuTek Corp. at 29 kGy.
  • the needle can then be used to pull the attached thread or threads into the skin adjacent to or within the stria.
  • the needle would then pull the thread through the skin such that the thread is located where the needle was previously inserted.
  • More than one thread can be used to treat the stria in order to achieve the desired fill effect (two to four or more threads).
  • the threads can also be placed perpendicular or oblique to the stria, for example, to form a cross-hatching pattern.
  • the stria may be visibly lessened and/or have a smoother appearance upon thread hydration.
  • Example 12 NMR study to determine the ratio of BDDE derivative to HA in cross-linked hydrogels
  • the ratio of BDDE to the disaccharide subunit of HA was determined by comparing the peak from the inner methylene hydrogens of 1 ,4-butanediol at 1.6 ppm to the acetyl methyl group of N- acetylglucosylamine at 2.0 ppm. At equal molar amounts of BDDE and disaccharide subunit these peak areas should integrate to 4 and 3, respectively.
  • the results with the 8% HA hydrogel gave peak areas integrating to 0.75 and 3, respectively, which corresponds to about 0.19 mole of BDDE per mole disaccharide subunit.
  • the results with the 10% HA hydrogel gave peak areas integrating to 0.72 and 3, respectively, which corresponds to about 0.18 mole of BDDE per mole disaccharide subunit.
  • Example 13 Effect of cross-linking on in vivo persistency of the thread - Animal Data
  • Sterilized hyaluronic acid threads produced via the following methods were placed in an animal and evaluated for in vivo persistency.
  • MW 1.47 MDa
  • BDDE 1,4-butanediol diglycidyl ether
  • Threads in Test Articles 1 and 2 were rinsed in Tris buffer (50 mM Tris, 150 mM NaCl) containing 100 mM ascorbic acid, threads in Test Articles 3 and 4 were rinsed in Tris buffer (50 mM Tris, 150 mM NaCl) containing 100 mM Vitamin E, threads inTest Articles 5 and 6 were rinsed in water prior to final drying (air dried). Threads in Test Articles 7 and 8 were prepared in 10 mM Tris buffer (pH 7) rather than 10 mM sodium bicarbonate buffer (pH 10) and were rinsed in water prior to final drying. Dried threads were cylindrical in shape, 0.006- 0.008" in diameter and 1.0-1.5" in length.
  • Test Articles were terminally sterilized via e-beam irradiation.
  • Test Articles 1 and 3 received an irradiation dose of 4 kGy.
  • Test Articles 2 and 4 received an irradiation dose of 20 kGy.
  • Test Articles 6 and 8 received an irradiation dose of 20 kGy frozen.
  • Test Articles 5 and 7 were processed in an aseptic-like environment and were not terminally sterilized.
  • a 0.75% w/w hyaluronic acid (1.7 MDa) solution was prepared by dissolving the HA in 10 mM TRIS buffer (pH 7). Butanediol diglycidyl ether (BDDE) was added to the HA solution and the solution was stirred overnight. The ratio of BDDE to HA was 2: 1.
  • the substantially cross-linked HA solution was then dialyzed against excess deionized water using a dialysis membrane with a molecular weight cut-off of about 12 to about 14 KDa. The dialyzed solution was then lyophilized to obtain dry substantially cross-linked hyaluronic acid.
  • the dry cross-linked hyaluronic acid (2.0 g) was exposed to 25 KGy e-beam (Irradiation temperature 1 - 3 °C), formulated to 16% solids (w/w) in 10 mM TRIS buffer (pH 7.00), extruded and dried for about 48 hrs at ambient temperature.
  • Test Article 9 was irradiated after cross-linking at 25kGy, 0.020" diameter, processed in an aseptic-like environment and non-terminally sterilized.
  • Test Article 10 was irradiated after cross- linking at 25kGy, 0.010" diameter, processed in an aseptic-like environment and non-terminally sterilized.
  • Test Article 11 was 0.020" in diameter, processed in an aseptic-like environment and non- terminally sterilized.
  • Test Article 12 was irradiated after cross-linking at 25kGy, 0.020" diameter, processed in an aseptic-like environment and non-terminally sterilized.
  • Test Article 13 was irradiated after cross-linking at 25kGy, 0.010" diameter, processed in an aseptic-like environment and non- terminally sterilized.
  • Test Article 14 was 0.020" in diameter, processed in an aseptic-like environment and non-terminally sterilized.
  • Test Articles 9-14 were implanted in rabbits. Skin segments containing a total of 20 treated sites were removed from each animal. Select specimens (4/group/timepoint taken from each thread(s) of Test Article 9-14 treated sites) were processed and analyzed. Complete resorption of the threads of Test Articles 9, 10, and 13 occurred by 7 days. Complete resorption of the threads of Test Article 12 occurred between 7 and 30 days. Nearly complete or complete resorption of the threads of Test Article 14 had occurred and partial resorption of the threads of Test Article 1 1 had occurred by 30 days.
  • Test Articles 15-20 were prepared as follows. Cross linked threads of diameter between 0.008 inches and 0.010 inches was made by forming a gel with a concentration of 10% hyaluronic acid and 4% BDDE by weight relative to total composition with the remainder comprised of 0.1 N sodium hydroxide. The ratio of BDDE to HA in the cross-linked gel was 0.18 mole of BDDE per mole disaccharide subunit. After rinsing, presizing, lyophilizing, and combining with noncross-linked binder, the gel was then extruded into a thread form by using a 20G nozzle. The wet thread is then dried for about 48 hrs to provide a dry thread. Table 6. Test Article Composition/Processing
  • PB 10 mM sodium phosphate buffer, pH 6
  • Test Articles were successfully assessed for degradation by macroscopic observation and by histology analysis. All Test Articles were identifiable by macroscopic observation through 90 days, but with the exception of Test Article 20, identification was inconsistent at 135 and 180 days.
  • Test Article 20 was quantitatively analyzed and by cross-sectional area persisted without significant change at 270 days.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Materials Engineering (AREA)
  • Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

Cette invention porte d'une façon générale sur des fils comprenant de l'acide hyaluronique réticulé, sur des procédés optimisés de fabrication de tels fils et sur des procédés d'utilisation des fils en traitement de strie.
PCT/US2014/024441 2013-03-12 2014-03-12 Fils d'acide hyaluronique réticulé pour le traitement de stries WO2014165113A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361778008P 2013-03-12 2013-03-12
US61/778,008 2013-03-12

Publications (1)

Publication Number Publication Date
WO2014165113A1 true WO2014165113A1 (fr) 2014-10-09

Family

ID=51659067

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/024441 WO2014165113A1 (fr) 2013-03-12 2014-03-12 Fils d'acide hyaluronique réticulé pour le traitement de stries

Country Status (1)

Country Link
WO (1) WO2014165113A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9421198B2 (en) 2013-07-30 2016-08-23 Teoxane Composition comprising hyaluronic acid and mepivacaine
WO2018020501A1 (fr) * 2016-07-27 2018-02-01 Marbelle Threads Ltd. Fils d'acide hyaluronique réticulé et d'hydroxyapatite
CN114351289A (zh) * 2021-12-31 2022-04-15 中国科学院苏州纳米技术与纳米仿生研究所 一种透明质酸纤维及其制备方法和应用
US11532806B2 (en) 2014-04-01 2022-12-20 The Research Foundation For The State University Of New York Electrode materials that include an active composition of the formula MgzMxOy for group II cation-based batteries

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4957744A (en) * 1986-10-13 1990-09-18 Fidia, S.P.A. Cross-linked esters of hyaluronic acid
US20050136122A1 (en) * 2003-12-22 2005-06-23 Anika Therapeutics, Inc. Crosslinked hyaluronic acid compositions for tissue augmentation
US20110224164A1 (en) * 2010-03-12 2011-09-15 Allergan Industrie, Sas Fluid compositions for improving skin conditions
US8147811B1 (en) * 1999-06-29 2012-04-03 Fidia Farmaceutici S.P.A. Use of hyaluronic acid derivatives in pharmaceutical preparations and biomaterials for the prevention and treatment of cutaneous scars
WO2012054311A1 (fr) * 2010-10-20 2012-04-26 Tautona Group Lp Fils d'acide hyaluronique réticulé, et leurs procédés de préparation et d'utilisation

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4957744A (en) * 1986-10-13 1990-09-18 Fidia, S.P.A. Cross-linked esters of hyaluronic acid
US8147811B1 (en) * 1999-06-29 2012-04-03 Fidia Farmaceutici S.P.A. Use of hyaluronic acid derivatives in pharmaceutical preparations and biomaterials for the prevention and treatment of cutaneous scars
US20050136122A1 (en) * 2003-12-22 2005-06-23 Anika Therapeutics, Inc. Crosslinked hyaluronic acid compositions for tissue augmentation
US20110224164A1 (en) * 2010-03-12 2011-09-15 Allergan Industrie, Sas Fluid compositions for improving skin conditions
WO2012054311A1 (fr) * 2010-10-20 2012-04-26 Tautona Group Lp Fils d'acide hyaluronique réticulé, et leurs procédés de préparation et d'utilisation

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9421198B2 (en) 2013-07-30 2016-08-23 Teoxane Composition comprising hyaluronic acid and mepivacaine
US9498562B1 (en) 2013-07-30 2016-11-22 Teoxane Composition comprising hyaluronic acid and mepivacaine
US9789226B2 (en) 2013-07-30 2017-10-17 Teoxane Composition comprising hyaluronic acid and mepivacaine
US9925309B2 (en) 2013-07-30 2018-03-27 Teoxane Composition comprising hyaluronic acid and mepivacaine
US10322212B2 (en) 2013-07-30 2019-06-18 Teoxane Composition comprising hyaluronic acid and mepivacaine
US10413637B2 (en) 2013-07-30 2019-09-17 Teoxane Composition comprising hyaluronic acid and mepivacaine
US10786601B2 (en) 2013-07-30 2020-09-29 Teoxane Composition comprising hyaluronic acid and mepivacaine
US11406738B2 (en) 2013-07-30 2022-08-09 Teoxane Composition comprising hyaluronic acid and mepivacaine
US11532806B2 (en) 2014-04-01 2022-12-20 The Research Foundation For The State University Of New York Electrode materials that include an active composition of the formula MgzMxOy for group II cation-based batteries
WO2018020501A1 (fr) * 2016-07-27 2018-02-01 Marbelle Threads Ltd. Fils d'acide hyaluronique réticulé et d'hydroxyapatite
CN114351289A (zh) * 2021-12-31 2022-04-15 中国科学院苏州纳米技术与纳米仿生研究所 一种透明质酸纤维及其制备方法和应用
CN114351289B (zh) * 2021-12-31 2024-03-19 中国科学院苏州纳米技术与纳米仿生研究所 一种透明质酸纤维及其制备方法和应用

Similar Documents

Publication Publication Date Title
EP2766056B1 (fr) Fils d'acide hyaluronique réticulé et procédés d'utilisation de ces derniers
US20150209265A1 (en) Spherical forms of cross-linked hyaluronic acid and methods of use thereof
US20150327972A1 (en) Soft tissue augmentation threads and methods of use thereof
US11702484B2 (en) Method for manufacturing a shaped cross-linked hyaluronic acid product
US20160213813A1 (en) Threads of cross-linked hyaluronic acid and methods of uses thereof
EP2979709B1 (fr) Fils d'acide hyaluronique réticulé et utilisation de ceux-ci
Qiao et al. Preparation of printable double-network hydrogels with rapid self-healing and high elasticity based on hyaluronic acid for controlled drug release
WO2011109130A1 (fr) Fils d'acide hyaluronique et leurs méthodes d'utilisation
WO2008072230A1 (fr) Nouveaux mélanges injectables de chitosans formant des hydrogels
EP2294126A1 (fr) Mélanges de chitosans formant un hydrogel injectable
WO2014165113A1 (fr) Fils d'acide hyaluronique réticulé pour le traitement de stries
Al-Sibani et al. Effect of hyaluronic acid initial concentration on cross-linking efficiency of hyaluronic acid–based hydrogels used in biomedical and cosmetic applications
NZ623909B2 (en) Threads of cross-linked hyaluronic acid and methods of use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14778070

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14778070

Country of ref document: EP

Kind code of ref document: A1